-- 根据FactSet调查的分析师报告，百健（Biogen，股票代码：BIIB）的平均评级为“增持”，平均目标价为215.86美元。 （报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）
Price: $191.38, Change: $-3.00, Percent Change: -1.54%
Related Articles
Australia
Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $478.09, Change: $+11.83, Percent Change: +2.54%
$TMO
Australia
JPMorgan Adjusts Price Target on Royal Caribbean Group to $345 From $341, Maintains Overweight Rating
Royal Caribbean Group (RCL) has an average rating of overweight and mean price target of $345.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $266.70, Change: $+12.69, Percent Change: +5.00%
$RCL
Australia
HSBC Cuts Microsoft Price Target to $571 From $593
Microsoft (MSFT) has an average rating of Buy and mean price target of $562.51, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $403.97, Change: $-20.50, Percent Change: -4.83%
$MSFT